Tìm theo
Omalizumab
Các tên gọi khác (1) :
  • Ig gamma-1 chain C region
Thuốc chống dị ứng
Thuốc Gốc
Biotech
CAS: 242138-07-4
ATC: R03DX05
ĐG : Genentech Inc. , http://www.gene.com
CTHH: C6450H9916N1714O2023S38
PTK: 145058.2000
A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6450H9916N1714O2023S38
Phân tử khối
145058.2000
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Độ kỵ nước
-0.432
Điểm đẳng điện tích
7.03
Dược Lực Học : Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.
Cơ Chế Tác Dụng : A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.
Dược Động Học :

▧ Volume of Distribution :
* 78 ± 32 mL/kg
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system.
▧ Route of Elimination :
Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.
▧ Half Life :
26 days
Chỉ Định : For treatment of asthma caused by allergies
Tương Tác Thuốc :
  • Belimumab Avoid combination due to enhanced toxic effects of monoclonal antibodies.
  • Denosumab Monitor therapy due to increased risk of infections consequent to increased adverse effects of immunosuppressants.
  • Leflunomide Consider modifying therapy due to increased adverse effects of leflunomide including hematological toxicity.
  • Natalizumab Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
  • Pimecrolimus Avoid combination due to enhanced adverse effects of immunosuppressants.
  • Roflumilast Consider therapy modification due to enhanced immunosuppressive effects.
  • Sipuleucel-T Monitor therapy due to diminished therapeutic effect of sipuleucel-t.
  • Tacrolimus Avoid combination due to enhanced adverse toxic effects.
  • Tofacitinib Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
  • Trastuzumab Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
Liều Lượng & Cách Dùng : Powder, for solution - Subcutaneous
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Xolair 150 mg vial
    Giá bán buôn : USD >715.42
    Đơn vị tính : vial
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00043
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/50242-040-62
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/J00228
PharmGKB
http://www.pharmgkb.org/drug/PA164752253
Wikipedia
http://en.wikipedia.org/wiki/Omalizumab
RxList
http://www.rxlist.com/cgi/generic/xolair.htm
Drugs.com
http://www.drugs.com/cdi/omalizumab.html
... loading
... loading